Medscape InDiscussion: Type 2 Diabetes

Follow Medscape InDiscussion: Type 2 Diabetes
Share on
Copy link to clipboard

Type 2 diabetes management has never been as evidence-based as it is today, so we invited leading endocrinologist Dr Silvio Inzucchi to encapsulate key findings in this first Medscape InDiscussion series for type 2 diabetes. Busy healthcare professionals

Medscape


    • Apr 24, 2025 LATEST EPISODE
    • monthly NEW EPISODES
    • 22m AVG DURATION
    • 16 EPISODES


    More podcasts from Medscape

    Search for episodes from Medscape InDiscussion: Type 2 Diabetes with a specific topic:

    Latest episodes from Medscape InDiscussion: Type 2 Diabetes

    S3 Episode 4: Heart Failure, Incretin Therapies, and Type 2 Diabetes

    Play Episode Listen Later Apr 24, 2025 21:37


    Drs Carol H. Wysham and Christopher M. Kramer discuss heart failure and type 2 diabetes, and the role of incretin therapies in the management of HFpEF. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002048. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources The Incidence of Congestive Heart Failure in Type 2 Diabetes: An Update https://pubmed.ncbi.nlm.nih.gov/15277411/ Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease https://pubmed.ncbi.nlm.nih.gov/34601960/ Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update https://pubmed.ncbi.nlm.nih.gov/31167558/ Insulin Resistance and Hyperinsulinaemia in Diabetic Cardiomyopathy https://pubmed.ncbi.nlm.nih.gov/26678809/ Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024 https://pubmed.ncbi.nlm.nih.gov/38078592/ The Paradox of Low BNP Levels in Obesity https://pubmed.ncbi.nlm.nih.gov/21523383 Tirzepatide for Heart Failure With Preserved Ejection Fraction and Obesity https://pubmed.ncbi.nlm.nih.gov/39555826/ Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials https://pubmed.ncbi.nlm.nih.gov/35050311/ Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF https://pubmed.ncbi.nlm.nih.gov/38294187/ Heart Failure With Preserved Ejection Fraction: Mechanisms and Treatment Strategies https://pubmed.ncbi.nlm.nih.gov/34379445/ Obesity and Heart Failure With Preserved Ejection Fraction: New Insights and Pathophysiological Targets https://pubmed.ncbi.nlm.nih.gov/35880317/ Epidemiology of Heart Failure in Diabetes: A Disease in Disguise https://pubmed.ncbi.nlm.nih.gov/38334818/ Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction and Obesity https://pubmed.ncbi.nlm.nih.gov/37622681/ Mechanisms of Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure With Preserved Ejection Fraction https://pubmed.ncbi.nlm.nih.gov/37674356/ Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction https://pubmed.ncbi.nlm.nih.gov/39225278/ Effects of Tirzepatide on Circulatory Overload and End-Organ Damage in Heart Failure With Preserved Ejection Fraction and Obesity: A Secondary Analysis of the SUMMIT Trial https://pubmed.ncbi.nlm.nih.gov/39551891/ Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, a Preserved Ejection Fraction, and Obesity https://pubmed.ncbi.nlm.nih.gov/39556714/ Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy https://pubmed.ncbi.nlm.nih.gov/39566869/6 Spironolactone for Heart Failure With Preserved Ejection Fraction https://pubmed.ncbi.nlm.nih.gov/24716680/

    S3 Episode 3: 2025 ADA Updates: Comorbidities, Dental Care, Weight Loss, Sexual Dysfunction, and CGM Use for Type 2 Diabetes

    Play Episode Listen Later Mar 25, 2025 24:58


    Drs Carol H. Wysham and Rozalina G. McCoy discuss the 2025 updates of the American Diabetes Association, including comorbidities, dental care, sexual dysfunction, and CGM use. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002047. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Standards of Care in Diabetes-2025 https://diabetesjournals.org/care/issue/48/Supplement_1 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2025 https://pubmed.ncbi.nlm.nih.gov/39651988/ 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2025 https://pubmed.ncbi.nlm.nih.gov/39651976/ The Simplified Nutritional Appetite Questionnaire (SNAQ) as a Screening Tool for Risk of Malnutrition: Optimal Cutoff, Factor Structure, and Validation in Healthy Community-Dwelling Older Adults https://pubmed.ncbi.nlm.nih.gov/32967354/ Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide: The STEP 1 Trial Extension https://pubmed.ncbi.nlm.nih.gov/35441470/ 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025 https://pubmed.ncbi.nlm.nih.gov/39651989/ 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2025 https://pubmed.ncbi.nlm.nih.gov/39651974/

    S3 Episode 2: Treating Type 2 Diabetes in an Aging Population: Geriatric Syndromes, Comorbidities, and Treatment De-escalation

    Play Episode Listen Later Feb 25, 2025 22:45


    Drs Carol H. Wysham and Medha Munshi discuss type 2 diabetes in older adults, understanding geriatric syndromes and how they impact care, and when to de-escalate treatment. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002046. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Worldwide Trends in Diabetes Prevalence and Treatment From 1990 to 2022: A Pooled Analysis of 1108 Population-Representative Studies With 141 Million Participants https://pubmed.ncbi.nlm.nih.gov/39549716/ National Diabetes Statistics Report https://www.cdc.gov/diabetes/php/data-research/index.html Home Modifications for Older Adults: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/36655622/ Geriatric Syndromes in Older Adults With Diabetes https://pubmed.ncbi.nlm.nih.gov/36948783/ The Relationship Between CGM-Derived Metrics, A1C, and Risk of Hypoglycemia in Older Adults With Type 1 Diabetes https://pubmed.ncbi.nlm.nih.gov/32461211/ Glycemic Control and Hypoglycemia in Patients Treated With Insulin Pump Therapy: An Observational Study https://pubmed.ncbi.nlm.nih.gov/32832557/

    S3 Episode 1: Screening and Management of Metabolic Dysfunction-Associated Fatty Liver Disease in Endocrine Practice

    Play Episode Listen Later Feb 25, 2025 21:49


    Drs Carol H. Wysham and Scott Isaacs discuss incorporating the screening and management of metabolic dysfunction–associated steatotic liver disease in endocrine practice. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002045. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review https://pubmed.ncbi.nlm.nih.gov/37700494/ Fibrosis-4 (FIB-4) Calculator https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4 Liver Fibrosis Assessment: MR and US Elastography https://pubmed.ncbi.nlm.nih.gov/34687329/ Using the FIB-4, Automatically Calculated, Followed by the ELF Test in Second Line to Screen Primary Care Patients for Liver Disease https://pubmed.ncbi.nlm.nih.gov/38806580/ American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) https://pubmed.ncbi.nlm.nih.gov/35569886/ Mediterranean Diet and Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/29785077/ Drug Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress and Direction https://pubmed.ncbi.nlm.nih.gov/39470028/ Current Status of Glucagon-Like Peptide-1 Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Clinical Perspective https://pubmed.ncbi.nlm.nih.gov/39801787/ Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/ Update on the Applications and Limitations of Alpha-Fetoprotein for Hepatocellular Carcinoma https://pubmed.ncbi.nlm.nih.gov/35110946/

    S2 Episode 6: What's Next? Emerging Trends in Type 2 Diabetes Management

    Play Episode Listen Later Jun 1, 2023 24:13


    Join Drs Carol Wysham and Silvio Inzucchi as they discuss how type 2 diabetes management has evolved over the years, and the most promising developments on the horizon. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982419). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Continuous Glucose Monitoring in Persons With Type 2 Diabetes Not Using Insulin https://pubmed.ncbi.nlm.nih.gov/34633261/ Macrovascular Complications of Type 2 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/30961498/ Rate of Decline in Kidney Function and Known Age-of-Onset or Duration of Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34282181/ Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/26378978/ Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27299675/ Tirzepatide Prescribing Information https://uspl.lilly.com/mounjaro/mounjaro.html#pi Glycemic Targets: Standards of Care in Diabetes-2023 https://pubmed.ncbi.nlm.nih.gov/36507646/ 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines https://pubmed.ncbi.nlm.nih.gov/30879355/ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update https://pubmed.ncbi.nlm.nih.gov/35963508/ 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension https://pubmed.ncbi.nlm.nih.gov/30165516/ The Role of BNP Testing in Heart Failure https://pubmed.ncbi.nlm.nih.gov/17168346/ Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) Rationale and Design https://pubmed.ncbi.nlm.nih.gov/32916609/ A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes (SOUL) https://clinicaltrials.gov/ct2/show/NCT03914326 GLP-1 Receptor Agonists and Kidney Protection https://pubmed.ncbi.nlm.nih.gov/31159279/ Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study https://pubmed.ncbi.nlm.nih.gov/31589290/ A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6) https://clinicaltrials.gov/ct2/show/NCT04537923 The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD https://pubmed.ncbi.nlm.nih.gov/34406410/ Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease https://pubmed.ncbi.nlm.nih.gov/19523535/ Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/30090738/

    S2 Episode 5: Weight Management as a Goal in Type 2 Diabetes Care

    Play Episode Listen Later May 3, 2023 20:27


    Join Drs Carol Wysham and Carel le Roux for practical, actionable strategies when targeting weight management as a key goal in type 2 diabetes prevention and treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982418). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources UK Prospective Diabetes Study https://www.dtu.ox.ac.uk/ukpds/ National Diabetes Prevention Program https://www.cdc.gov/diabetes/prevention/index.html The Finnish Diabetes Prevention Study (DPS): Lifestyle Intervention and 3-Year Results on Diet and Physical Activity https://pubmed.ncbi.nlm.nih.gov/14633807/ The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It https://pubmed.ncbi.nlm.nih.gov/16855180/ Antidiabetics, Glucagon-like Peptide-1 Agonists https://reference.medscape.com/drugs/antidiabetics-glucagon-like-peptide-1-agonists Semaglutide (Rx) https://reference.medscape.com/drug/ozempic-rybelsus-wegovy-semaglutide-1000174 Weight Management: Obesity to Diabetes https://pubmed.ncbi.nlm.nih.gov/28848305/ Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management https://pubmed.ncbi.nlm.nih.gov/36750526/ Tirzepatide Once Weekly for the Treatment of Obesity https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

    S2 Episode 4: Tech Geek: The Latest in Type 2 Diabetes Wearables and Devices

    Play Episode Listen Later Apr 4, 2023 20:32


    Opportunities abound to upgrade your technology in type 2 diabetes patient care. Join Dr Carol Wysham and nurse practitioner Davida F. Kruger in a discussion on the latest wearables and devices. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982417). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources SGLT2 Inhibitors and GLP-1 Receptor Agonists: Established and Emerging Indications https://pubmed.ncbi.nlm.nih.gov/34216571/ How May GIP Enhance the Therapeutic Efficacy of GLP-1? https://pubmed.ncbi.nlm.nih.gov/32396843/ Continuous Glucose Monitoring in Primary Care – Are We There? https://pubmed.ncbi.nlm.nih.gov/34845158/ Finger-Stick Glucose Monitoring: Issues of Accuracy and Specificity https://pubmed.ncbi.nlm.nih.gov/20351231/ FreeStyle Libre 3: "Almost Like Wearing Nothing" https://www.medscape.com/viewarticle/979580 FDA Okays Dexcom G7 Continuous Glucose Monitoring System https://www.medscape.com/viewarticle/985274 InPen https://www.medtronicdiabetes.com/products/inpen-smart-insulin-pen-system Patch Pumps for Insulin https://pubmed.ncbi.nlm.nih.gov/30070604/

    S2 Episode 3: Advances in Chronic Kidney Disease Care in Type 2 Diabetes

    Play Episode Listen Later Mar 1, 2023 24:05


    Join Dr Carol Wysham and Dr Katherine Tuttle as they discuss advances in kidney disease management in patients living with type 2 diabetes. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982416). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification https://pubmed.ncbi.nlm.nih.gov/12859163/ KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32998798/ Prevalence of Non-diabetic Kidney Disease and Inability of Clinical Predictors to Differentiate It From Diabetic Kidney Disease: Results From a Prospectively Performed Renal Biopsy Study https://pubmed.ncbi.nlm.nih.gov/36517108/ Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) https://repository.niddk.nih.gov/studies/edic/ UK Prospective Diabetes Study https://www.dtu.ox.ac.uk/ukpds/ Kidney Disease and Obesity: Epidemiology, Mechanisms and Treatment https://pubmed.ncbi.nlm.nih.gov/28090083/ Diet and Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/31728497/ SGLT2 Inhibitors and the Diabetic Kidney https://pubmed.ncbi.nlm.nih.gov/27440829/ GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms https://pubmed.ncbi.nlm.nih.gov/32694999/ Cardiovascular Outcomes Trials: A Paradigm Shift in the Current Management of Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/35927730/ Effects of Long-term Antihypertensive Treatment on Kidney Function in Diabetic Nephropathy https://pubmed.ncbi.nlm.nih.gov/4077229/ A Randomized Trial of Intensive Versus Standard Blood-Pressure Control https://pubmed.ncbi.nlm.nih.gov/26551272/ Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus https://pubmed.ncbi.nlm.nih.gov/20228401/ Effects of a Fixed Combination of Perindopril and Indapamide on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes Mellitus (the ADVANCE Trial): A Randomised Controlled Trial https://pubmed.ncbi.nlm.nih.gov/17765963/ Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) https://pubmed.ncbi.nlm.nih.gov/36202661/ Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/27299675/ Empagliflozin in Heart Failure With a Preserved Ejection Fraction https://pubmed.ncbi.nlm.nih.gov/34449189/ Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure https://pubmed.ncbi.nlm.nih.gov/32865377/

    S2 Episode 2: Recognizing the Signs: Heart Failure and Type 2 Diabetes

    Play Episode Listen Later Feb 1, 2023 23:08


    Join Dr Carol Wysham and Dr Javed Butler as they discuss the stealth complication of heart failure in patients with type 2 diabetes, including subtle signs and symptoms of heart failure and the importance of early detection and treatment. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982415). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1504720 Framingham Heart Study https://www.framinghamheartstudy.org/ Heart Failure https://emedicine.medscape.com/article/163062-overview Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association https://diabetesjournals.org/care/article/45/7/1670/147048/Heart-Failure-An-Underappreciated-Complication-of Brain-Type Natriuretic Peptide (BNP) https://emedicine.medscape.com/article/2087425-overview The Effect of Spironolactone on Morbidity and Mortality in Patients With Severe Heart Failure https://www.nejm.org/doi/full/10.1056/NEJM199909023411001 Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms https://www.nejm.org/doi/full/10.1056/nejmoa1009492 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001063

    S2 Episode 1: How to Care for Older Adults With Type 2 Diabetes

    Play Episode Listen Later Feb 1, 2023 20:23


    Drs Carol Wysham and Medha N. Munshi discuss the unique challenges and strategies when treating older adults with type 2 diabetes. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982414). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Type 2 Diabetes Mellitus https://emedicine.medscape.com/article/117853-overview Diabetes in Older Adults: A Consensus Report https://agsjournals.onlinelibrary.wiley.com/doi/full/10.1111/jgs.12035 Geriatrics https://www.medscape.com/resource/geriatric Hypoglycemia https://emedicine.medscape.com/article/122122-overview Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline https://academic.oup.com/jcem/article/104/5/1520/5413486 Sodium-Glucose Cotransporter 2 Inhibitors: An Overview https://www.medscape.com/viewarticle/892957_9 Euglycemic Diabetic Ketoacidosis https://www.ncbi.nlm.nih.gov/books/NBK554570/

    Future Type 2 Diabetes Drugs: Exciting and a Little Scary

    Play Episode Listen Later Jul 12, 2022 22:25


    Who are the likely beneficiaries of more nuanced diabetes treatments, and how might these agents advance diabetes care? Silvio Inzucchi, MD, and guest Joshua Neumiller, PharmD, dig deep into recent drug developments. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/963278). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment Patient Education Interventions Improve A1C Values https://pubmed.ncbi.nlm.nih.gov/35426637/ Therapeutics for Type-2 Diabetes Mellitus: A Glance at the Recent Inclusions and Novel Agents Under Development for Use in Clinical Practice https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474306/ Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S39/138909/3-Prevention-or-Delay-of-Type-2-Diabetes-and

    Type 2 Diabetes Care Equity: What Can You Do?

    Play Episode Listen Later Jun 15, 2022 21:29


    Are health equity and better outcomes within reach for all patients with type 2 diabetes? Drs Enrique Caballero and Silvio Inzucchi discuss how we can change the status quo. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963277). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources National Health and Nutrition Examination Survey https://www.cdc.gov/nchs/about/factsheets/factsheet_nhanes.htm Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016 https://jamanetwork.com/journals/jama/fullarticle/2757817 Diabetes mellitus in the Pima Indians: Genetic and evolutionary considerations https://pubmed.ncbi.nlm.nih.gov/6624895/ HbA1c Performance in African Descent Populations in the United States With Normal Glucose Tolerance, Prediabetes, or Diabetes: A Scoping Review https://www.cdc.gov/pcd/issues/2021/20_0365.htm

    Better Ways to Sustain Weight Loss in Type 2 Diabetes

    Play Episode Listen Later May 18, 2022 24:15


    Patients with type 2 diabetes and obesity have more options today than ever before. Join host Dr Silvio Inzucchi and obesity expert Dr Ania Jastreboff as they discuss how to successfully support weight loss in people with type 2 diabetes. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963276). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Long-term Drug Treatment for Obesity: A Systematic and Clinical Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928674/ What's New in Medications for Weight Management for People With Diabetes https://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/new-in-medications-for-weight-management FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014 https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 Diabetes and Obesity -- Inextricable Diseases https://www.heraldopenaccess.us/openaccess/diabetes-and-obesity-inextricable-diseases Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline https://academic.oup.com/jcem/article/100/2/342/2813109

    How to Reduce Renal Risk in Type 2 Diabetes

    Play Episode Listen Later Apr 13, 2022 25:27


    Want to prevent kidney disease progression in patients with type 2 diabetes? Join host Dr Silvio Inzucchi and nephrologist Dr David Cherney as they unpack the how and why behind current recommendations. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963275). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease https://kdigo.org/wp-content/uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf Introduction: ADA Standards of Medical Care https://diabetesjournals.org/care/issue/45/Supplement_1 Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Medical Care in Diabetes — 2022 https://diabetesjournals.org/care/article/45/Supplement_1/S39/138909/3-Prevention-or-Delay-of-Type-2-Diabetes-and

    A Brave New World in Type 2 Diabetes Treatment and Beyond

    Play Episode Listen Later Mar 22, 2022 21:28


    Where are the biggest cardiovascular benefits for your patients with type 2 diabetes? Host Dr Silvio Inzucchi and cardiologist Dr Mikhail Kosiborod reveal winning strategies — for managing much more than just type 2 diabetes. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963270). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources New ACC Guidance on CVD Risk Reduction in Diabetes https://www.medscape.com/viewarticle/935218 Type 2 Diabetes in Adults: Management https://www.nice.org.uk/guidance/ng28/chapter/Recommendations#blood-glucose-management Type 2 Diabetes and Causes of Sudden Cardiac Death: A Systematic Review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525691/ Cardiometabolic Medicine – the US Perspective on a New Subspecialty https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410029/pdf/xce-9-070.pdf Antidiabetics, Glucagon-like Peptide-1 Agonists https://reference.medscape.com/drugs/antidiabetics-glucagon-like-peptide-1-agonists Antidiabetics, SGLT2 Inhibitors https://reference.medscape.com/drugs/antidiabetics-sglt2-inhibitors Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/31189511/ Mechanistic Insights Regarding the Role of SGLT2 Inhibitors and GLP1 Agonist Drugs on Cardiovascular Disease in Diabetes https://pubmed.ncbi.nlm.nih.gov/31381891/ SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Systematic Review and Meta-analysis of Cardiovascular Outcome Trials https://pubmed.ncbi.nlm.nih.gov/30424892/ Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial https://pubmed.ncbi.nlm.nih.gov/33736819/ Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1812389 CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis https://diabetesjournals.org/care/article/39/7/1108/37341/CV-Protection-in-the-EMPA-REG-OUTCOME-Trial-A Worldwide Inertia to the Use of Cardiorenal Protective Glucose-Lowering Drugs (SGLT2i and GLP-1 RA) in High-Risk Patients with Type 2 Diabetes https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01154-w Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial https://pubmed.ncbi.nlm.nih.gov/30291013/ High-Sensitivity C-Reactive Protein https://emedicine.medscape.com/article/2094831-overview#:~:text=hs%2DCRP%20is%20an%20important,predicts%20mortality%20and%20cardiac%20complications. Optimal Use of SGLT2 Inhibitors and GLP-1 Agonists: 5 Things to Know https://www.medscape.com/viewarticle/960356 Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34215025/ Coronary Artery Calcification on CT Scanning https://emedicine.medscape.com/article/352189-overview

    High-Impact Type 2 Diabetes Treatment Guidelines

    Play Episode Listen Later Mar 22, 2022 23:46


    Huge improvements in treatments for type 2 diabetes are outlined in recent diabetes guidelines. Get the upshot on best evidence from leading experts Drs Silvio Inzucchi and Rita Kalyani. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/963267). The topics and discussions are planned, produced, and reviewed independently of our advertiser. This podcast is intended only for US healthcare professionals. Resources Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 https://diabetesjournals.org/care/article/45/Supplement_1/S125/138908/9-Pharmacologic-Approaches-to-Glycemic-Treatment Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes https://www.fda.gov/media/71297/download Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1504720 Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1603827 Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042007 Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis of the EMPEROR-Reduced and DAPA-HF Trials https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31824-9/fulltext The SGLT2 Inhibitor Dapagliflozin in Heart Failure With Preserved Ejection Fraction: A Multicenter Randomized Trial https://www.nature.com/articles/s41591-021-01536-x A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) (REMODEL) https://clinicaltrials.gov/ct2/show/NCT04865770

    Claim Medscape InDiscussion: Type 2 Diabetes

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel